Prospective longitudinal multi-omics study of palbociclib resistance in hormone receptor+/HER2-metastatic breast cancer.

被引：5
|
作者：
Park, Yeon Hee
Im, Seock-Ah
Park, Kyunghee
Wen, Ji
Min, Ahrum
Bonato, Vinicius
Park, Seri
Ram, Sripad
Lee, Dae-Won
Kim, Ji-Yeon
Lee, Kyung-Hun
Lee, Won-Chul
Lee, Jisook
Kim, Hyunseon
Lee, Won-Woo
Choi, Yoon-La
Weinrich, Scott
Ryu, Han Suk
Park, Woong-Yang
Kan, Zhengyan
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Canc Res Inst, Coll Med, Seoul, South Korea
[3] Samsung Genome Inst, Samsung Med Ctr, Seoul, South Korea
[4] Pfizer, Oncol Res & Dev, San Diego, CA USA
[5] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Canc Res Inst, Seoul, South Korea
[6] Pfizer, Biostat, San Diego, CA USA
[7] SAIHST, Dept Hlth Sci & Technol, Seoul, South Korea
[8] Pfizer, Drug Safety R&D, San Diego, CA USA
[9] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
[10] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea
[11] Seoul Natl Univ Hosp, Seoul, South Korea
[12] Pfizer, Seoul, South Korea
[13] Sungkyunkwan Univ, Dept Pathol & Translat Genom, Samsung Med Ctr, Sch Med, Seoul, South Korea
[14] Pfizer Inc, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.1013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1013
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    Kahraman, Seda
    Erul, Enes
    Seyyar, Mustafa
    Gumusay, Ozge
    Bayram, Ertugrul
    Demirel, Burcin Cakan
    Acar, Omer
    Aksoy, Sercan
    Baytemur, Naziyet Kose
    Sahin, Elif
    Cabuk, Devrim
    Basaran, Gul
    Paydas, Semra
    Yaren, Arzu
    Guven, Deniz Can
    Erdogan, Atike Pinar
    Demirci, Umut
    Yasar, Alper
    Bayoglu, Ibrahim Vedat
    Hizal, Mutlu
    Gulbagci, Burcu
    Paksoy, Nail
    Davarci, Sena Ece
    Yilmaz, Funda
    Dogan, Ozlem
    Orhan, Sibel Oyucu
    Kayikcioglu, Erkan
    Aytac, Ali
    Keskinkilic, Merve
    Mocan, Eda Eylemer
    Unal, Olcun Umit
    Aydin, Esra
    Yucel, Hakan
    Isik, Deniz
    Eren, Onder
    Uluc, Basak Oyan
    Ozcelik, Melike
    Hacibekiroglu, Ilhan
    Aydiner, Adnan
    Demir, Hacer
    Oksuzoglu, Berna
    Cilbir, Ebru
    Cubukcu, Erdem
    Cetin, Bulent
    Oktay, Esin
    Erol, Cihan
    Okutur, Sadi Kerem
    Yildirim, Nilgun
    Alkan, Ali
    Selcukbiricik, Fatih
    [J]. FUTURE ONCOLOGY, 2023, : 727 - 736
  • [32] FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Walker, Amanda J.
    Wedam, Suparna
    Amiri-Kordestani, Laleh
    Bloomquist, Erik
    Tang, Shengui
    Sridhara, Rajeshwari
    Chen, Wei
    Palmby, Todd R.
    Zirkelbach, Jeanne Fourie
    Fu, Wentao
    Liu, Qi
    Tilley, Amy
    Kim, Geoffrey
    Kluetz, Paul G.
    McKee, Amy E.
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (20) : 4968 - 4972
  • [33] Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2-Metastatic Breast Cancer
    Jeselsohn, Rinath
    Fu, Jingxin
    Ren, Yue
    Mahtani, Reshma
    Ma, Cynthia
    DeMichele, Angela
    Cristofanilli, Massimo
    Meisel, Jane
    Miller, Kathy
    Abdou, Yara
    Riley, Elizabeth
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya
    Ko, Naomi
    Liu, Yuan
    Burstein, Harold
    DeMeo, Michelle
    Tolaney, Sara
    Mayer, Erica
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [34] Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer
    Li, Nanxin
    Du, Ella X.
    Chu, Lihao
    Peeples, Miranda
    Xie, Jipan
    Barghout, Victoria
    Tang, Derek H.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) : 1167 - 1178
  • [35] Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Morikawa, Aki
    Henry, N. Lynn
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3591 - 3596
  • [36] Exploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR) HER2-metastatic breast cancer (MBC)
    Tolaney, S. M.
    Cortes, J.
    Dickler, M. N.
    Zamora, E.
    Caldwell, C. W.
    Nguyen, T. S.
    Nanda, S.
    Koustenis, A.
    Rugo, H. S.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [37] Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (HR+)/HER2-metastatic breast cancer
    Fitzgerald, D. M.
    Henderson, L. E.
    Isakoff, S. J.
    Moy, B.
    Oh, K.
    Shih, H. A.
    Dias-Santagata, D.
    Borger, D. R.
    Iafrate, A. J.
    Brastianos, P. K.
    Bardia, A.
    Juric, D.
    [J]. CANCER RESEARCH, 2017, 77
  • [38] Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer
    Go, Makiko
    Kimura, Michio
    Yamada, Shiori
    Usami, Eiseki
    Noguchi, Yoshihiro
    Yoshimura, Tomoaki
    [J]. JOURNAL OF PHARMACY PRACTICE, 2024,
  • [39] Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2-breast cancer
    Wander, S. A.
    Spring, L. M.
    Stein, C. R.
    Yuen, M.
    Zangardi, M.
    O'Shaughnessy, J.
    Bardia, A.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [40] Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer
    Wang, Kang
    Li, Lun
    Franch-Exposito, Sebastia
    Le, Xin
    Tang, Jun
    Li, Qing
    Wu, Qianxue
    Bassaganyas, Laia
    Camps, Jordi
    Zhang, Xiang
    Li, Hongyuan
    Foukakis, Theodoros
    Xiang, Tingxiu
    Wu, Jiong
    Ren, Guosheng
    [J]. MOLECULAR ONCOLOGY, 2022, 16 (12) : 2413 - 2431
12345